Danysh HE, Navai SA, Scheurer ME, Hunt R, Venkatramani R. Malignant melanoma incidence among children and adolescents in Texas and SEER 13, 1995-2013. Pediatr Blood Cancer. 2019 Jun;66(6):e27648. doi: 10.1002/pbc.27648
Peckham-Gregory EC, Danysh HE, Brown AL, Eckstein O, Grimes A, Chakraborty R, Lubega J, McClain KL, Allen CE, Scheurer ME, Lupo PJ. Evaluation of maternal and perinatal characteristics on childhood lymphoma risk: a population-based case-control study. Pediatr Blood Cancer. 2017 May;64(5). doi: 10.1002/pbc.26321
Sankaran H, Danysh HE, Scheurer ME, Okcu MF, Skapek SX, Hawkins DS, Spector LG, Erhardt EB, Grufferman S, Lupo PJ. The role of childhood infections and immunizations on childhood rhabdomyosarcoma: a report from the children's oncology group. Pediatr Blood Cancer. 2016 Sep;63(9):1557-62. doi: 10.1002/pbc.26065
Rees CA, Keating EM, Lukolyo H, Danysh HE, Scheurer ME, Mehta PS, Lubega J, Slone JS, Baylor Pediatric HIV-Related Malignancy Consortium. Mapping the epidemiology of Kaposi sarcoma and non-Hodgkin lymphoma among children in sub-Saharan Africa: a review. Pediatr Blood Cancer. 2016 Aug;63(8):1325-31. doi: 10.1002/pbc.26021
Danysh H, Zhang K, Mitchell LE, Scheurer ME, Lupo PL. Maternal residential proximity to roadways during pregnancy and childhood central nervous system tumors: a population-based assessment in Texas, 2003-2009. Presented at the 47th Congress of the International Society of Paediatric Oncology; October 10, 2015. Cape Town, South Africa. [abstract] Pediatr Blood Cancer. 2015 Nov; 62(S4). Previously presented at the Brain Tumor Epidemiology Consortium 2015 Annual Conference.
Danysh HE, Mitchell LE, Zhang K, Scheurer ME, Lupo PJ. Traffic-related air pollution and the incidence of childhood central nervous system tumors: Texas, 2001-2009. Pediatr Blood Cancer. 2015 Sep;62(9):1572-8. doi: 10.1002/pbc.25549
Danysh HE, Mitchell LE, Zhang K, Scheurer ME, Lupo PL. A statewide assessment of childhood central nervous system tumors and traffic-related air pollution. Presented at the 46th Congress of the International Society of Paediatric Oncology (SIOP); October 2014. Toronto, Canada. [abstract] Pediatr Blood Cancer. 2014 Dec; 61(S2). Previously presented at the Brain Tumor Epidemiology Consortium 2014 Annual Conference. doi: 10.1002/pbc.25314
Williams VS, Nelson LM, Fehnel SE, MacDougall J, Carson RT, Tourkodimitris S, Kurtz C, Baird MJ, Johnston JM. Psychometric validation of symptom severity measures in irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2014 Aug;40(3):298-308. doi: 10.1111/apt.12830
Rubin DT, Mody R, Davis KL, Wang CC. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther. 2014 May;39(10):1143-55. doi: 10.1111/apt.12727
Huerta C, Rivero E, Montoro MA, García-Rodriguez LA. Risk factors for intestinal ischaemia among patients registered in a UK primary care database: a nested case-control study. Aliment Pharmacol Ther. 2011 Apr;33(8):969-78. doi: 10.1111/j.1365-2036
Earnshaw SR, Klok RM, Iyer S, McDade C. Methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness--a cost-effectiveness analysis. Aliment Pharmacol Ther. 2010 Apr 1;31(8):911-21.
Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K, Mangel AW, Fehnel SE. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008 Jun 15;27(12):1224-32.
Tennis P, Andrews E, Hickman P, Miller D, Hollis KA, Cook S. The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow-up programme. Aliment Pharmacol Ther. 2007 Feb 1;25(3):317-22.
Miller DP, Bennett L, Hollis KA, Tennis P, Cook SF, Andrews E. A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme. Aliment Pharmacol Ther. 2006 Sep 1;24(5):869-78.
Mangel AW, Fehnel SE. Global endpoints in functional gastrointestinal disease. Aliment Pharmacol Ther. 2005 Dec 1;22(11-12):1162-3.
Andrews EB, Eaton SC, Hollis KA, Hopkins JS, Ameen VZ, Hamm LR, Mangel AW, Tennis P, Cook SF. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther. 2005 Nov 10;22:935-42.
Vakil N, Hahn B, McSorley DJ. Recurrent symptoms and gastro-oesophageal reflux disease in patient with duodenal ulcer treated for helicobacter pylori infection. Aliment Pharmacol Ther. 2000 Jan;14(1):45-51.
Camilleri M, Mayer EA, Drossman DA, Heath AT, Dukes GE, McSorley DJ, Kong S, Mangel AW, Northcutt AR. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999 Sep;13(9):1149-59.
Peterson WL, Ciociola AA, Sykes DL, McSorley DJ, Webb DD. Ranitidine bismuth citrate (tritec) plus clarithromycin is effective for healing duodenal ulcers, eradicating h.pylori, and reducing ulcer recurrence. Aliment Pharmacol Ther. 1996;10(3):251-61.
Burudi EM, Karanja SM, Njue AI, Githiori JB, Ndung'u JM. Establishment of a partly DFMO-sensitive primate model of Trypanosoma rhodesiense sleeping sickness. Acta Trop. 1995 Mar;59(1):71-3.